Economic information and modeling report

Modeling overview

4 evidence topics · 1 source

Summary

The retained comparator economic assessment evaluates Cinryze, Haegarda, and Takhzyro against no prophylaxis. ICER's 2021 observational real-world evidence update reported incremental costs per QALY gained of $30,070,000, $13,430,000, and $12,370,000, respectively. These are comparator cost-effectiveness estimates, not annual treatment costs, acquisition prices, or budget-impact estimates for lonvoguran ziclumeran. The report cautions that small denominators can produce extreme incremental cost-effectiveness ratios.

Comparator economic assessment: reference strategy

“No prophylaxis” (opens the source at this quote in a new tab)

Comparator-treatment economic assessment: observational real-world evidence update

Treatment	“Observational RWE Update Cost per QALY gained”
“Cinryze”	“$30,070,000”
“Haegarda”	“$13,430,000”
“Takhzyro”	“$12,370,000”

Comparator economic assessment: interpretation of incremental ratios

“Due to ratio properties of incremental cost-effectiveness ratios, results can become extreme with small denominators.” (opens the source at this quote in a new tab)